MX365591B - Formulacion de metaxalona. - Google Patents

Formulacion de metaxalona.

Info

Publication number
MX365591B
MX365591B MX2016001019A MX2016001019A MX365591B MX 365591 B MX365591 B MX 365591B MX 2016001019 A MX2016001019 A MX 2016001019A MX 2016001019 A MX2016001019 A MX 2016001019A MX 365591 B MX365591 B MX 365591B
Authority
MX
Mexico
Prior art keywords
metaxalone
dosage forms
formulation
submicron
improved bioavailability
Prior art date
Application number
MX2016001019A
Other languages
English (en)
Other versions
MX2016001019A (es
Inventor
H William Bosch
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of MX2016001019A publication Critical patent/MX2016001019A/es
Publication of MX365591B publication Critical patent/MX365591B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen las formas de dosis de metaxalona que contienen partículas de tamaño sub-micra de metaxalona y los usos de las mismas. La formas de dosis de sub-micras han mejorado la bio-disponibilidad comparada con ciertas formas de dosis convencionales de metaxalona.
MX2016001019A 2013-07-22 2014-07-22 Formulacion de metaxalona. MX365591B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857199P 2013-07-22 2013-07-22
PCT/US2014/047701 WO2015013336A1 (en) 2013-07-22 2014-07-22 Formulation of metaxalone

Publications (2)

Publication Number Publication Date
MX2016001019A MX2016001019A (es) 2016-07-19
MX365591B true MX365591B (es) 2019-06-07

Family

ID=52393794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001019A MX365591B (es) 2013-07-22 2014-07-22 Formulacion de metaxalona.

Country Status (18)

Country Link
US (6) US20160159756A1 (es)
EP (1) EP3024440B1 (es)
JP (1) JP6453876B2 (es)
KR (1) KR20160039608A (es)
CN (1) CN105431136B (es)
AU (1) AU2014293193A1 (es)
BR (1) BR112016001395A8 (es)
CA (1) CA2918908A1 (es)
CL (1) CL2016000171A1 (es)
DK (1) DK3024440T3 (es)
HK (2) HK1222570A1 (es)
IL (1) IL243447A0 (es)
MX (1) MX365591B (es)
MY (1) MY181226A (es)
RU (1) RU2684914C2 (es)
SG (2) SG10201800491RA (es)
WO (1) WO2015013336A1 (es)
ZA (1) ZA201600408B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20200405693A1 (en) * 2019-06-25 2020-12-31 Primus Pharmaceuticals, Inc. Reduced dose metaxalone formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US7714006B1 (en) * 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
ES2430849T3 (es) * 2004-03-08 2013-11-22 Spiridon Spireas Formas de dosificación sólidas biodisponibles de metaxalona
WO2009019662A2 (en) * 2007-08-09 2009-02-12 Ranbaxy Laboratories Limited Oral metaxalone compositions
NZ595903A (en) * 2009-04-24 2014-03-28 Iceutica Pty Ltd A novel formulation of metaxalone
EP2421509B1 (en) * 2009-04-24 2017-11-22 Iceutica Pty Ltd. Production of encapsulated nanoparticles at high volume fractions
RU2499595C1 (ru) * 2012-07-03 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

Also Published As

Publication number Publication date
RU2016105763A (ru) 2017-08-29
US20190152930A1 (en) 2019-05-23
RU2684914C2 (ru) 2019-04-16
EP3024440A1 (en) 2016-06-01
SG10201800491RA (en) 2018-03-28
KR20160039608A (ko) 2016-04-11
SG11201600264TA (en) 2016-02-26
MY181226A (en) 2020-12-21
JP6453876B2 (ja) 2019-01-16
US20210101873A1 (en) 2021-04-08
US20160159756A1 (en) 2016-06-09
HK1222570A1 (zh) 2017-07-07
DK3024440T3 (en) 2019-03-11
CN105431136B (zh) 2020-03-24
JP2016527251A (ja) 2016-09-08
BR112016001395A8 (pt) 2020-01-14
US20220235017A1 (en) 2022-07-28
RU2016105763A3 (es) 2018-06-13
WO2015013336A1 (en) 2015-01-29
CN105431136A (zh) 2016-03-23
IL243447A0 (en) 2016-02-29
ZA201600408B (en) 2017-04-26
CL2016000171A1 (es) 2016-07-01
CA2918908A1 (en) 2015-01-29
EP3024440A4 (en) 2017-01-25
US20180148422A1 (en) 2018-05-31
HK1225301A1 (zh) 2017-09-08
BR112016001395A2 (pt) 2017-07-25
EP3024440B1 (en) 2018-11-28
AU2014293193A1 (en) 2016-01-28
US20240150304A1 (en) 2024-05-09
MX2016001019A (es) 2016-07-19

Similar Documents

Publication Publication Date Title
PH12019500176A1 (en) Heterocyclic compounds and ther uses
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
TWD180370S (zh) 落地式逆滲透淨水器
MX2015012416A (es) Compuestos heterociclicos y sus usos.
IN2013MU03641A (es)
UY34829A (es) Nueva dosificación y formulación
IN2014CH00840A (es)
MX363378B (es) Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.
IN2014DN06617A (es)
MX2016001019A (es) Formulacion de metaxalona.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
MX2017007596A (es) Procedimiento para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina; y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
MX2015010774A (es) Formulaciones nanoparticuladas y macroparticuladas.
IN2013CH05770A (es)
PH12015502015A1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
AU366478S (en) Handbag
TWD178255S (zh) 齒間刷
IN2013CH02437A (es)
TWD166583S (zh) 帳篷之部分
IN2013DE02958A (es)
IN2013CH05769A (es)
IN2013CH00453A (es)

Legal Events

Date Code Title Description
FG Grant or registration